Share Price and Basic Stock Data
Last Updated: January 2, 2026, 8:04 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Omaxe Ltd operates within the construction, contracting, and engineering sector, with a current market capitalization of ₹1,481 Cr and a share price standing at ₹80.9. The company reported total sales of ₹773 Cr for the year ending March 2023, following a significant decline from ₹1,839 Cr in March 2018. Quarterly sales figures showed fluctuations, with the latest quarter ending September 2023 recording sales of ₹266 Cr, a decline from ₹289 Cr in the preceding quarter. However, projections indicate a sharp increase in revenue, with anticipated sales of ₹1,614 Cr for March 2024. This resurgence is likely driven by ongoing projects and a recovery in the real estate sector, which has faced challenges in recent years. The company’s sales trajectory reflects a volatile market environment yet showcases potential for growth as it capitalizes on increased demand in the construction sector.
Profitability and Efficiency Metrics
Omaxe Ltd has faced notable challenges in profitability, with a reported net profit of -₹651 Cr and an operating profit margin (OPM) of -53%. The operational difficulties are evident in the operating profit for the year ending March 2025, which is projected to be -₹608 Cr, indicating a continued struggle with cost management and revenue generation. The interest coverage ratio stood at -2.72x, reflecting the company’s inability to cover interest expenses from its earnings. Furthermore, the return on equity (ROE) at an astonishing 506% is misleading due to negative net profits, highlighting the imbalance between equity and profitability. The company’s cash conversion cycle (CCC) of 73 days indicates a relatively efficient management of inventory and receivables, though the high operating losses suggest that efficiency gains have not translated into profitability.
Balance Sheet Strength and Financial Ratios
The balance sheet of Omaxe Ltd reveals a precarious financial position, with total borrowings amounting to ₹1,419 Cr against negative reserves of -₹740 Cr. This situation raises concerns about the company’s ability to sustain operations without incurring additional debt. The debt-to-equity ratio stands at -1.73, indicating that the company is heavily leveraged, and its long-term debt to equity ratio of -1.16 suggests an unsustainable financial structure. The book value per share has deteriorated to -₹23.53, reflecting a significant erosion of shareholder equity. Despite these challenges, the company’s current ratio of 0.95 suggests it can meet its short-term obligations, albeit with limited buffer. The operating cash flow remains negative, further complicating the ability to fund operations or investments without additional financing.
Shareholding Pattern and Investor Confidence
Omaxe Ltd maintains a stable shareholding pattern, with promoters holding 74.14% of the equity, indicating strong control over the company’s decisions. Foreign Institutional Investors (FIIs) have reduced their stake from 9.15% in December 2022 to 6.06% by September 2025, reflecting waning confidence among international investors. Domestic Institutional Investors (DIIs) have similarly decreased their holdings, currently at 1.56%. The public shareholding has increased to 18.23%, suggesting a growing interest among retail investors despite the company’s financial struggles. The number of shareholders has fluctuated, reaching 49,331 by September 2025, which may indicate a mix of new entrants and existing investors holding on in hope of recovery. This distribution highlights both a challenge in attracting institutional interest and an opportunity for retail investors as the company attempts to navigate its financial difficulties.
Outlook, Risks, and Final Insight
The outlook for Omaxe Ltd hinges on its ability to stabilize operations and reverse its profitability trends. The potential for recovery exists, particularly if the company can capitalize on the expected increase in sales for March 2024. However, risks remain pronounced, including high leverage, negative profitability, and declining investor confidence. The construction sector is expected to see growth, yet Omaxe must navigate its internal challenges effectively, including managing costs and improving operational efficiency. Should the company succeed in restructuring its financial obligations and enhancing its project execution capabilities, it may regain investor trust and market position. Conversely, failure to address these critical issues could lead to further declines in financial health and shareholder value.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Modern Engineering and Projects Ltd | 53.3 Cr. | 34.5 | 49.9/22.5 | 5.08 | 39.4 | 0.00 % | 20.5 % | 25.9 % | 10.0 |
| Modis Navnirman Ltd | 675 Cr. | 339 | 409/220 | 82.3 | 46.5 | 0.00 % | 12.9 % | 9.88 % | 10.0 |
| Modulex Construction Technologies Ltd | 161 Cr. | 23.2 | 35.7/18.0 | 44.7 | 0.00 % | 2.51 % | 1.54 % | 10.0 | |
| MPDL Ltd | 31.6 Cr. | 42.6 | 79.3/38.0 | 127 | 0.00 % | 2.87 % | 4.16 % | 10.0 | |
| IITL Projects Ltd | 32.9 Cr. | 66.0 | 77.9/47.1 | 2.12 | 0.00 % | 16.6 % | % | 10.0 | |
| Industry Average | 17,893.67 Cr | 252.26 | 76.27 | 138.29 | 0.16% | 16.34% | 21.32% | 21.41 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 119 | 244 | 289 | 213 | 266 | 599 | 536 | 342 | 389 | 289 | 541 | 282 | 321 |
| Expenses | 187 | 346 | 399 | 306 | 333 | 637 | 682 | 493 | 613 | 416 | 647 | 452 | 490 |
| Operating Profit | -68 | -102 | -109 | -93 | -67 | -37 | -146 | -151 | -224 | -127 | -106 | -170 | -169 |
| OPM % | -57% | -42% | -38% | -43% | -25% | -6% | -27% | -44% | -58% | -44% | -20% | -60% | -53% |
| Other Income | 3 | 10 | 9 | 7 | 4 | 3 | 7 | 44 | 9 | 11 | 12 | 16 | 26 |
| Interest | 31 | 27 | 26 | 31 | 29 | 32 | 38 | 42 | 45 | 57 | 51 | 67 | 65 |
| Depreciation | 16 | 16 | 16 | 16 | 10 | 15 | 14 | 7 | 7 | 10 | 12 | 7 | 8 |
| Profit before tax | -112 | -136 | -143 | -132 | -103 | -82 | -191 | -157 | -267 | -183 | -157 | -228 | -216 |
| Tax % | -22% | -20% | -27% | -19% | -18% | -12% | -25% | -6% | -10% | -18% | -5% | -19% | -23% |
| Net Profit | -87 | -109 | -104 | -106 | -84 | -72 | -144 | -147 | -239 | -150 | -149 | -186 | -166 |
| EPS in Rs | -4.78 | -5.79 | -5.77 | -5.81 | -4.61 | -3.66 | -7.93 | -8.06 | -13.10 | -8.23 | -8.11 | -10.16 | -9.11 |
Last Updated: December 29, 2025, 6:34 pm
Below is a detailed analysis of the quarterly data for Omaxe Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 321.00 Cr.. The value appears strong and on an upward trend. It has increased from 282.00 Cr. (Jun 2025) to 321.00 Cr., marking an increase of 39.00 Cr..
- For Expenses, as of Sep 2025, the value is 490.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 452.00 Cr. (Jun 2025) to 490.00 Cr., marking an increase of 38.00 Cr..
- For Operating Profit, as of Sep 2025, the value is -169.00 Cr.. The value appears strong and on an upward trend. It has increased from -170.00 Cr. (Jun 2025) to -169.00 Cr., marking an increase of 1.00 Cr..
- For OPM %, as of Sep 2025, the value is -53.00%. The value appears strong and on an upward trend. It has increased from -60.00% (Jun 2025) to -53.00%, marking an increase of 7.00%.
- For Other Income, as of Sep 2025, the value is 26.00 Cr.. The value appears strong and on an upward trend. It has increased from 16.00 Cr. (Jun 2025) to 26.00 Cr., marking an increase of 10.00 Cr..
- For Interest, as of Sep 2025, the value is 65.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 67.00 Cr. (Jun 2025) to 65.00 Cr., marking a decrease of 2.00 Cr..
- For Depreciation, as of Sep 2025, the value is 8.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 7.00 Cr. (Jun 2025) to 8.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Sep 2025, the value is -216.00 Cr.. The value appears strong and on an upward trend. It has increased from -228.00 Cr. (Jun 2025) to -216.00 Cr., marking an increase of 12.00 Cr..
- For Tax %, as of Sep 2025, the value is -23.00%. The value appears to be improving (decreasing) as expected. It has decreased from -19.00% (Jun 2025) to -23.00%, marking a decrease of 4.00%.
- For Net Profit, as of Sep 2025, the value is -166.00 Cr.. The value appears strong and on an upward trend. It has increased from -186.00 Cr. (Jun 2025) to -166.00 Cr., marking an increase of 20.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is -9.11. The value appears strong and on an upward trend. It has increased from -10.16 (Jun 2025) to -9.11, marking an increase of 1.05.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:52 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,605 | 1,414 | 1,386 | 1,627 | 1,839 | 1,167 | 1,121 | 476 | 618 | 773 | 1,614 | 1,561 | 1,433 |
| Expenses | 1,378 | 1,180 | 1,144 | 1,343 | 1,579 | 1,038 | 924 | 594 | 665 | 1,077 | 1,958 | 2,169 | 2,005 |
| Operating Profit | 226 | 234 | 242 | 284 | 260 | 128 | 198 | -119 | -47 | -303 | -343 | -608 | -572 |
| OPM % | 14% | 17% | 17% | 17% | 14% | 11% | 18% | -25% | -8% | -39% | -21% | -39% | -40% |
| Other Income | 30 | 34 | 54 | 59 | 59 | 34 | 28 | 39 | 20 | 25 | 21 | 76 | 65 |
| Interest | 131 | 144 | 147 | 155 | 169 | 74 | 108 | 161 | 121 | 113 | 130 | 195 | 240 |
| Depreciation | 10 | 14 | 10 | 9 | 9 | 9 | 73 | 63 | 47 | 65 | 54 | 37 | 38 |
| Profit before tax | 116 | 110 | 139 | 179 | 141 | 79 | 44 | -305 | -194 | -457 | -507 | -764 | -784 |
| Tax % | 32% | 46% | 45% | 41% | 39% | 38% | 319% | -23% | -17% | -23% | -20% | -10% | |
| Net Profit | 79 | 60 | 77 | 105 | 85 | 49 | -97 | -235 | -162 | -351 | -406 | -685 | -651 |
| EPS in Rs | 4.29 | 3.28 | 4.20 | 5.58 | 4.59 | 2.68 | -5.32 | -12.86 | -8.72 | -19.02 | -22.01 | -37.51 | -35.61 |
| Dividend Payout % | 12% | 15% | 17% | 13% | 15% | 26% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -24.05% | 28.33% | 36.36% | -19.05% | -42.35% | -297.96% | -142.27% | 31.06% | -116.67% | -15.67% | -68.72% |
| Change in YoY Net Profit Growth (%) | 0.00% | 52.38% | 8.03% | -55.41% | -23.31% | -255.61% | 155.69% | 173.33% | -147.73% | 101.00% | -53.05% |
Omaxe Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 7% |
| 3 Years: | 36% |
| TTM: | -14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -63% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -4% |
| 5 Years: | 5% |
| 3 Years: | -5% |
| 1 Year: | -30% |
| Return on Equity | |
|---|---|
| 10 Years: | -11% |
| 5 Years: | -39% |
| 3 Years: | -76% |
| Last Year: | -498% |
Last Updated: September 5, 2025, 11:55 am
Balance Sheet
Last Updated: December 4, 2025, 1:44 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 183 | 183 | 183 | 183 | 183 | 183 | 183 | 183 | 183 | 183 | 183 | 183 | 183 |
| Reserves | 1,746 | 1,794 | 1,848 | 1,936 | 2,014 | 1,558 | 1,456 | 1,222 | 1,062 | 715 | 298 | -388 | -740 |
| Borrowings | 1,299 | 1,346 | 1,328 | 1,503 | 1,802 | 1,856 | 1,672 | 1,530 | 1,128 | 1,107 | 796 | 796 | 1,419 |
| Other Liabilities | 3,225 | 3,585 | 4,353 | 4,704 | 4,129 | 7,163 | 7,239 | 8,108 | 9,545 | 11,555 | 12,546 | 14,300 | 14,866 |
| Total Liabilities | 6,453 | 6,908 | 7,712 | 8,326 | 8,128 | 10,760 | 10,549 | 11,042 | 11,918 | 13,560 | 13,822 | 14,891 | 15,728 |
| Fixed Assets | 131 | 118 | 600 | 604 | 604 | 599 | 747 | 671 | 627 | 582 | 565 | 606 | 595 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 16 | 20 | 22 | 12 | 12 | 12 | 12 | 12 | 13 | 14 | 29 | 21 | 20 |
| Other Assets | 6,306 | 6,769 | 7,091 | 7,710 | 7,512 | 10,149 | 9,789 | 10,359 | 11,278 | 12,964 | 13,228 | 14,264 | 15,112 |
| Total Assets | 6,453 | 6,908 | 7,712 | 8,326 | 8,128 | 10,760 | 10,549 | 11,042 | 11,918 | 13,560 | 13,822 | 14,891 | 15,728 |
Below is a detailed analysis of the balance sheet data for Omaxe Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 183.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 183.00 Cr..
- For Reserves, as of Sep 2025, the value is -740.00 Cr.. The value appears to be worsening (becoming more negative). It has deteriorated from -388.00 Cr. (Mar 2025) to -740.00 Cr., marking a decline of 352.00 Cr..
- For Borrowings, as of Sep 2025, the value is 1,419.00 Cr.. The value appears to be increasing, which may not be favorable. However, Reserves are negative, which is a major warning sign. It has increased from 796.00 Cr. (Mar 2025) to 1,419.00 Cr., marking an increase of 623.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 14,866.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 14,300.00 Cr. (Mar 2025) to 14,866.00 Cr., marking an increase of 566.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 15,728.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 14,891.00 Cr. (Mar 2025) to 15,728.00 Cr., marking an increase of 837.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 595.00 Cr.. The value appears to be declining and may need further review. It has decreased from 606.00 Cr. (Mar 2025) to 595.00 Cr., marking a decrease of 11.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 20.00 Cr.. The value appears to be declining and may need further review. It has decreased from 21.00 Cr. (Mar 2025) to 20.00 Cr., marking a decrease of 1.00 Cr..
- For Other Assets, as of Sep 2025, the value is 15,112.00 Cr.. The value appears strong and on an upward trend. It has increased from 14,264.00 Cr. (Mar 2025) to 15,112.00 Cr., marking an increase of 848.00 Cr..
- For Total Assets, as of Sep 2025, the value is 15,728.00 Cr.. The value appears strong and on an upward trend. It has increased from 14,891.00 Cr. (Mar 2025) to 15,728.00 Cr., marking an increase of 837.00 Cr..
However, the Borrowings (1,419.00 Cr.) are higher than the Reserves (-740.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 225.00 | 233.00 | 241.00 | 283.00 | 259.00 | 127.00 | 197.00 | -120.00 | -48.00 | -304.00 | -1,139.00 | -1,404.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 197 | 199 | 208 | 235 | 158 | 110 | 111 | 298 | 227 | 182 | 81 | 73 |
| Inventory Days | 16,214 | |||||||||||
| Days Payable | 1,755 | |||||||||||
| Cash Conversion Cycle | 197 | 199 | 208 | 235 | 158 | 110 | 111 | 298 | 227 | 182 | 14,539 | 73 |
| Working Capital Days | 470 | 601 | 570 | 547 | 461 | 532 | 508 | 911 | 424 | 156 | -62 | -333 |
| ROCE % | 8% | 8% | 9% | 10% | 8% | 4% | 5% | -5% | -3% | -16% | -23% | -61% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -37.51 | -22.01 | -19.02 | -8.72 | -12.86 |
| Diluted EPS (Rs.) | -37.51 | -22.01 | -19.02 | -8.72 | -12.86 |
| Cash EPS (Rs.) | -35.45 | -19.24 | -15.62 | -6.29 | -9.39 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | -23.53 | 14.42 | 37.44 | 56.57 | 65.43 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | -23.53 | 14.42 | 37.44 | 56.57 | 65.43 |
| Revenue From Operations / Share (Rs.) | 85.35 | 88.26 | 42.28 | 33.78 | 26.01 |
| PBDIT / Share (Rs.) | -29.07 | -17.64 | -15.23 | -1.46 | -4.36 |
| PBIT / Share (Rs.) | -31.08 | -20.61 | -18.81 | -4.01 | -7.83 |
| PBT / Share (Rs.) | -41.76 | -27.74 | -24.97 | -10.63 | -16.66 |
| Net Profit / Share (Rs.) | -37.46 | -22.20 | -19.20 | -8.84 | -12.86 |
| NP After MI And SOA / Share (Rs.) | -37.51 | -22.01 | -19.02 | -8.72 | -12.86 |
| PBDIT Margin (%) | -34.06 | -19.98 | -36.02 | -4.32 | -16.77 |
| PBIT Margin (%) | -36.41 | -23.35 | -44.47 | -11.86 | -30.10 |
| PBT Margin (%) | -48.92 | -31.42 | -59.06 | -31.46 | -64.04 |
| Net Profit Margin (%) | -43.89 | -25.15 | -45.39 | -26.16 | -49.44 |
| NP After MI And SOA Margin (%) | -43.94 | -24.93 | -44.98 | -25.82 | -49.43 |
| Return on Networth / Equity (%) | 0.00 | -157.76 | -51.69 | -15.64 | -19.93 |
| Return on Capital Employeed (%) | -61.52 | -23.15 | -16.47 | -3.32 | -5.47 |
| Return On Assets (%) | -4.61 | -2.91 | -2.56 | -1.33 | -2.12 |
| Long Term Debt / Equity (X) | -1.16 | 1.95 | 0.98 | 0.42 | 0.67 |
| Total Debt / Equity (X) | -1.73 | 2.86 | 1.37 | 0.90 | 0.80 |
| Asset Turnover Ratio (%) | 0.10 | 0.11 | 0.06 | 0.04 | 0.03 |
| Current Ratio (X) | 0.95 | 1.02 | 1.07 | 1.10 | 1.17 |
| Quick Ratio (X) | 0.16 | 0.15 | 0.16 | 0.15 | 0.15 |
| Inventory Turnover Ratio (X) | 0.14 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | -2.72 | -2.48 | -2.47 | -0.22 | -0.49 |
| Interest Coverage Ratio (Post Tax) (X) | -2.51 | -2.12 | -2.11 | -0.33 | -0.45 |
| Enterprise Value (Cr.) | 1437.16 | 1855.26 | 1453.09 | 2188.62 | 2001.51 |
| EV / Net Operating Revenue (X) | 0.92 | 1.15 | 1.88 | 3.54 | 4.21 |
| EV / EBITDA (X) | -2.70 | -5.75 | -5.22 | -81.94 | -25.08 |
| MarketCap / Net Operating Revenue (X) | 0.91 | 1.03 | 1.18 | 2.37 | 2.59 |
| Price / BV (X) | -3.32 | 6.50 | 1.36 | 1.44 | 1.04 |
| Price / Net Operating Revenue (X) | 0.91 | 1.03 | 1.18 | 2.37 | 2.59 |
| EarningsYield | -0.48 | -0.24 | -0.38 | -0.10 | -0.19 |
After reviewing the key financial ratios for Omaxe Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -37.51. This value is below the healthy minimum of 5. It has decreased from -22.01 (Mar 24) to -37.51, marking a decrease of 15.50.
- For Diluted EPS (Rs.), as of Mar 25, the value is -37.51. This value is below the healthy minimum of 5. It has decreased from -22.01 (Mar 24) to -37.51, marking a decrease of 15.50.
- For Cash EPS (Rs.), as of Mar 25, the value is -35.45. This value is below the healthy minimum of 3. It has decreased from -19.24 (Mar 24) to -35.45, marking a decrease of 16.21.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -23.53. It has decreased from 14.42 (Mar 24) to -23.53, marking a decrease of 37.95.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -23.53. It has decreased from 14.42 (Mar 24) to -23.53, marking a decrease of 37.95.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 85.35. It has decreased from 88.26 (Mar 24) to 85.35, marking a decrease of 2.91.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -29.07. This value is below the healthy minimum of 2. It has decreased from -17.64 (Mar 24) to -29.07, marking a decrease of 11.43.
- For PBIT / Share (Rs.), as of Mar 25, the value is -31.08. This value is below the healthy minimum of 0. It has decreased from -20.61 (Mar 24) to -31.08, marking a decrease of 10.47.
- For PBT / Share (Rs.), as of Mar 25, the value is -41.76. This value is below the healthy minimum of 0. It has decreased from -27.74 (Mar 24) to -41.76, marking a decrease of 14.02.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -37.46. This value is below the healthy minimum of 2. It has decreased from -22.20 (Mar 24) to -37.46, marking a decrease of 15.26.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -37.51. This value is below the healthy minimum of 2. It has decreased from -22.01 (Mar 24) to -37.51, marking a decrease of 15.50.
- For PBDIT Margin (%), as of Mar 25, the value is -34.06. This value is below the healthy minimum of 10. It has decreased from -19.98 (Mar 24) to -34.06, marking a decrease of 14.08.
- For PBIT Margin (%), as of Mar 25, the value is -36.41. This value is below the healthy minimum of 10. It has decreased from -23.35 (Mar 24) to -36.41, marking a decrease of 13.06.
- For PBT Margin (%), as of Mar 25, the value is -48.92. This value is below the healthy minimum of 10. It has decreased from -31.42 (Mar 24) to -48.92, marking a decrease of 17.50.
- For Net Profit Margin (%), as of Mar 25, the value is -43.89. This value is below the healthy minimum of 5. It has decreased from -25.15 (Mar 24) to -43.89, marking a decrease of 18.74.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -43.94. This value is below the healthy minimum of 8. It has decreased from -24.93 (Mar 24) to -43.94, marking a decrease of 19.01.
- For Return on Networth / Equity (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 15. It has increased from -157.76 (Mar 24) to 0.00, marking an increase of 157.76.
- For Return on Capital Employeed (%), as of Mar 25, the value is -61.52. This value is below the healthy minimum of 10. It has decreased from -23.15 (Mar 24) to -61.52, marking a decrease of 38.37.
- For Return On Assets (%), as of Mar 25, the value is -4.61. This value is below the healthy minimum of 5. It has decreased from -2.91 (Mar 24) to -4.61, marking a decrease of 1.70.
- For Long Term Debt / Equity (X), as of Mar 25, the value is -1.16. This value is below the healthy minimum of 0.2. It has decreased from 1.95 (Mar 24) to -1.16, marking a decrease of 3.11.
- For Total Debt / Equity (X), as of Mar 25, the value is -1.73. This value is within the healthy range. It has decreased from 2.86 (Mar 24) to -1.73, marking a decrease of 4.59.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.10. It has decreased from 0.11 (Mar 24) to 0.10, marking a decrease of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 0.95. This value is below the healthy minimum of 1.5. It has decreased from 1.02 (Mar 24) to 0.95, marking a decrease of 0.07.
- For Quick Ratio (X), as of Mar 25, the value is 0.16. This value is below the healthy minimum of 1. It has increased from 0.15 (Mar 24) to 0.16, marking an increase of 0.01.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.14. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 0.14, marking an increase of 0.14.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -2.72. This value is below the healthy minimum of 3. It has decreased from -2.48 (Mar 24) to -2.72, marking a decrease of 0.24.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -2.51. This value is below the healthy minimum of 3. It has decreased from -2.12 (Mar 24) to -2.51, marking a decrease of 0.39.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,437.16. It has decreased from 1,855.26 (Mar 24) to 1,437.16, marking a decrease of 418.10.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.92. This value is below the healthy minimum of 1. It has decreased from 1.15 (Mar 24) to 0.92, marking a decrease of 0.23.
- For EV / EBITDA (X), as of Mar 25, the value is -2.70. This value is below the healthy minimum of 5. It has increased from -5.75 (Mar 24) to -2.70, marking an increase of 3.05.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.91. This value is below the healthy minimum of 1. It has decreased from 1.03 (Mar 24) to 0.91, marking a decrease of 0.12.
- For Price / BV (X), as of Mar 25, the value is -3.32. This value is below the healthy minimum of 1. It has decreased from 6.50 (Mar 24) to -3.32, marking a decrease of 9.82.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.91. This value is below the healthy minimum of 1. It has decreased from 1.03 (Mar 24) to 0.91, marking a decrease of 0.12.
- For EarningsYield, as of Mar 25, the value is -0.48. This value is below the healthy minimum of 5. It has decreased from -0.24 (Mar 24) to -0.48, marking a decrease of 0.24.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Omaxe Ltd:
- Net Profit Margin: -43.89%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -61.52% (Industry Average ROCE: 16.34%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0% (Industry Average ROE: 21.32%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -2.51
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.16
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 76.27)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: -1.73
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -43.89%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Construction, Contracting & Engineering | Shop No. 19-B, First Floor, Gurgaon Haryana 122001 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Rohtas Goel | Chairman & Non-Exe.Director |
| Mr. Mohit Goel | Managing Director |
| Mr. Vinit Goyal | Whole Time Director |
| Ms. Nishal Jain | Non Exe. Women Independent Director |
| Mr. Shridhar Rao | Ind. Non-Executive Director |
| Mr. Aroon Kumar Aggarwal | Ind. Non-Executive Director |
| Ms. Binitha Manohar Dalal | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Omaxe Ltd?
Omaxe Ltd's intrinsic value (as of 02 January 2026) is ₹1882.81 which is 2253.51% higher the current market price of ₹80.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹1,464 Cr. market cap, FY2025-2026 high/low of ₹114/62.5, reserves of ₹-740 Cr, and liabilities of ₹15,728 Cr.
What is the Market Cap of Omaxe Ltd?
The Market Cap of Omaxe Ltd is 1,464 Cr..
What is the current Stock Price of Omaxe Ltd as on 02 January 2026?
The current stock price of Omaxe Ltd as on 02 January 2026 is ₹80.0.
What is the High / Low of Omaxe Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Omaxe Ltd stocks is ₹114/62.5.
What is the Stock P/E of Omaxe Ltd?
The Stock P/E of Omaxe Ltd is .
What is the Book Value of Omaxe Ltd?
The Book Value of Omaxe Ltd is 30.4.
What is the Dividend Yield of Omaxe Ltd?
The Dividend Yield of Omaxe Ltd is 0.00 %.
What is the ROCE of Omaxe Ltd?
The ROCE of Omaxe Ltd is 61.4 %.
What is the ROE of Omaxe Ltd?
The ROE of Omaxe Ltd is 506 %.
What is the Face Value of Omaxe Ltd?
The Face Value of Omaxe Ltd is 10.0.